Replies to post #2968 on Enanta Pharmaceuticals Inc (ENTA)

[dewophile]

I think the panoramic trial is powered that they should be able to show efficacy on outcomes like hospitalization even with event rates much lower now in a more immune experienced population
If I were a pharma I would want to see the ensitrelvir data and then decide on 235 bc at this point you are talking only a few months (NIH is running the study so it’s not going to be suppressed long like epic-Sr
NIH of course could choose to fund 235 too if the data do suggest it might be better on efficacy than ensitrelvir